Journal profile · NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY
Clinical Psychopharmacology and Neuroscience
ISSN 1738-1088 · eISSN 2093-4327 · Korean College of Neuropsychopharmacology · SOUTH KOREA
Clinical Psychopharmacology and Neuroscience: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.38; fully open access; median 71 days to acceptance (95 articles, last 24 months); 74 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Psychopharmacology and Neuroscience is published by Korean College of Neuropsychopharmacology and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Schizophrenia research and treatment, Tryptophan and brain disorders and Treatment of Major Depression, together about 34.1% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.
Source: LetPub
Research area (LetPub): NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Schizophrenia research and treatmentMedicine13.3%
- Tryptophan and brain disordersNeuroscience10.6%
- Treatment of Major DepressionMedicine10.2%
- Bipolar Disorder and TreatmentMedicine8.5%
- Attention Deficit Hyperactivity DisorderMedicine6.4%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience5.1%
- Electroconvulsive Therapy StudiesMedicine4.7%
- Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesPsychology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Neurosciences | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Neurosciences | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Neurosciences | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.38LetPub ·
- CiteScore 2026-06
- 5.2LetPub ·
- SJR 2026-06
- 0.98LetPub ·
- SNIP 2026-06
- 1.05LetPub ·
- h-index
- 22LetPub ·
- h-index
- 59OpenAlex ·
- i10-index
- 462OpenAlex ·
- 2-year mean citedness
- 1.87OpenAlex ·
- Self-citation rate
- 8.8%LetPub ·
- Share of gold OA articles
- 99.56%LetPub ·
Volume
- Articles per year
- 73LetPub ·
Articles by year OpenAlex count · 1,090 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 73 | 73 | 9 |
| 2025 | 74 | 74 | 106 |
| 2024 | 64 | 64 | 280 |
| 2023 | 121 | 121 | 1,257 |
| 2022 | 80 | 80 | 924 |
| 2021 | 87 | 87 | 1,161 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
71 daysMedian, submission to acceptance · P25–P75 34 days – 110 days
- Acceptance to online
- median 38 days (95 articles)
- Submission to online
- median 115 days
- Sample
- 95 articles with submission and acceptance dates (168 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Korean College of Neuropsychopharmacology
- Country or region
- SOUTH KOREA
- Language
- English
- ISSN
- 1738-1088
- Electronic ISSN
- 2093-4327
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Clinical Psychopharmacology and Neuroscience
What CAS zone is Clinical Psychopharmacology and Neuroscience in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Psychopharmacology and Neuroscience is in Zone 4 of Medicine, and in Zone 4 of the minor category Neurosciences / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Psychopharmacology and Neuroscience?
The latest impact factor listed by LetPub is 3.38; CiteScore 5.2, h-index 59.
How long does peer review take at Clinical Psychopharmacology and Neuroscience?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 71 days (interquartile range 34–110 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Clinical Psychopharmacology and Neuroscience?
According to LetPub and DOAJ records, Clinical Psychopharmacology and Neuroscience is indexed in SCIE and Scopus.
Is Clinical Psychopharmacology and Neuroscience open access, and what is the APC?
Clinical Psychopharmacology and Neuroscience is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .